Anivive Wins FDA Approval for First Oral Canine Lymphoma Drug
LONG BEACH, Calif., June 26, 2026 Anivive Lifesciences has achieved a landmark milestone after the U.S. Food and Drug...
alpha-synuclein
Advertisement
NeuroSense PrimeC Shows Positive Phase 2 Alzheimer’s Biomarker Data
CAMBRIDGE, Mass., June 25, 2026 NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 randomized, double-blind, placebo-controlled...
Single-Molecule Proteomics Targets Alpha-Synuclein in Parkinson’s
January 28, 2026 — Nautilus Biotechnology, Weill Cornell Medicine–Qatar (WCM-Q), and The Michael J. Fox Foundation (MJFF) have launched...
AC Immune’s Phase 2 Data Shows Promise in Slowing Parkinson’s Progression
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
Advertisement
